SEARCH:
Print

Bavarian Nordic Reports Change in the Board of Directors

KVISTGAARD, Denmark, November 14, 2013 – Bavarian Nordic A/S (OMX: BAVA) – After having served as chairman of the board of Bavarian Nordic for 20 years, CEO Asger Aamund has announced that he will not seek re-election at the upcoming General Meeting on April 24, 2014. 

The board of directors intends, if re-elected, to nominate Dr. Gerard van Odijk as new chairman of the board of Bavarian Nordic. Dr. van Odijk is a Dutch national, born in 1957. He holds a medical degree from the State University of Utrecht. He is former President and CEO of Teva Pharmaceuticals Europe B.V. and has previously held various senior positions in GlaxoSmithKline. He currently serves as an independent advisor and board member in several international companies. Dr. van Odijk has been member of the board of directors of Bavarian Nordic since 2008.

Contacts

Asger Aamund, Chairman. Phone +45 40 78 19 11

About Bavarian Nordic

Bavarian Nordic is an international biotechnology company developing and manufacturing novel cancer immunotherapies and vaccines for infectious diseases. Lead product candidates are PROSTVAC®, an immunotherapy product candidate for advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 clinical trial and IMVAMUNE®, a non-replicating smallpox vaccine candidate in Phase 3 development, which is being developed and supplied for emergency use to the U.S. Strategic National Stockpile under a contract with the U.S. Government. IMVAMUNE is approved in the European Union under the trade name IMVANEX®.

Bavarian Nordic's shares are listed on NASDAQ OMX Copenhagen under the symbol BAVA (Reuters: BAVA.CO, Bloomberg: BAVA.DC). The company has a sponsored Level 1 ADR program listed in the US (OTC) under the symbol BVNRY.

For more information, visit www.bavarian-nordic.com.

Forward-looking statements

This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Company Announcement no. 21 / 2013